Literature DB >> 32376309

Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients.

Seong Eun Kim1, Hae Seong Jeong1, Yohan Yu1, Sung Un Shin1, Soosung Kim1, Tae Hoon Oh1, Uh Jin Kim2, Seung-Ji Kang2, Hee-Chang Jang2, Sook-In Jung3, Kyung-Hwa Park4.   

Abstract

From a total of 71 laboratory-confirmed cases, three presymptomatic patients and 10 patients with entirely asymptomatic infections were identified. In two of the three incubation period patients, the viral titer in the presymptomatic period was very high (Ct value<20). The median number of days to first negative RT-PCR in the asymptomatic carriers was 4.5 (range 2.5-9), and all asymptomatic carriers reached a first RT-PCR Ct>35 within 14 days after diagnosis. Patients who have COVID-19 may already be infectious before there are symptoms, and 14 days of isolation after diagnosis may be sufficient in entirely asymptomatic cases.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Asymptomatic carrier; COVID-19; Isolation; Presymptomatic; Viral kinetics

Mesh:

Year:  2020        PMID: 32376309      PMCID: PMC7196533          DOI: 10.1016/j.ijid.2020.04.083

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


An outbreak of a novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in Wuhan, China in December 2019 (Lu et al., 2020). This outbreak went on to become a public health emergency of international concern. The World Health Organization defines coronavirus disease 2019 (COVID-19) as the infectious disease caused by laboratory-confirmed SARS-CoV-2, diagnosed by real-time reverse transcription polymerase chain reaction (RT-PCR) (WHO, 2020). COVID-19 can present as an asymptomatic carrier state, an acute respiratory disease, or as pneumonia. Some studies have found that people infected with SARS-CoV-2 in the asymptomatic or presymptomatic period can be infectious (Bai et al., 2020, Mao et al., 2020). Current evidence on how long to quarantine asymptomatic carriers is limited. In a recent paper, Mao et al. reported reservations about the 14-day isolation period for asymptomatic carriers, because this period was based on observations of only two cases (Mao et al., 2020). The lack of isolation capacity in some countries is expected to lead to an explosive increase in COVID-19 cases. Here, we report the viral kinetics according to the absence or presence of symptoms. This study included patients with laboratory-confirmed COVID-19 admitted to the Affiliated Hospitals of Chonnam National University between February 4 and April 7, 2020. RT-PCR was positive if the cycle threshold (Ct) values of both the envelope (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2 were less than 35. Specimens were collected from all patients at least 2 days after hospitalization and physicians checked their symptoms and signs daily. Epidemiological and clinical information was obtained. Seventy-one patients were hospitalized for treatment or isolation. Patients who had any of the following features at quarantine release were analyzed: (1) asymptomatic carrier (n  = 10), i.e. those who had no symptoms in the 14 days preceding diagnosis until release from quarantine; (2) incubation period patients (n  = 3), i.e., those who were asymptomatic during the 14 days preceding diagnosis, but became symptomatic during quarantine. Table 1 shows the clinical characteristics of the patients analyzed. The median age of the asymptomatic carriers was 31 years (interquartile range 17.8–55.8 years).
Table 1

Clinical characteristics of presymptomatic patients with mild symptoms and asymptomatic carriers

PatientAge (years)SexUnderlying diseaseContact with confirmed COVID-19 caseIncubation perioda (days)Symptom-free period after admission (days)Maximal O2 supply (min/l)Pneumonia extent (max 24)Treatment
Incubation period patients with mild symptoms
 A20FNoneFamilyN/A200LPV/r
 B30MNoneReligious event4200None
 C30MHTNReligious event4100None
Asymptomatic carriersFrom contact to diagnosis (days)From diagnosis to hospitalization (days)
 D58MDMFamilyN/A200None
 E79FAsthma, osteoporosisMedical care10700None
 F8FNoneForeign visit, familyN/A200None
 G37MLiver donorForeign visit14b000None
 H48MDMReligious eventN/A200None
 I24FNoneReligious event20b100None
 J8FNoneFamilyN/A200None
 K21MNoneDormitory14b100None
 L55FNoneOccupational10700None
 M25FNoneForeign visitN/A100None

COVID-19, coronavirus disease; DM, diabetes mellitus; F, female; HTN, hypertension; M, male; N/A, not applicable; LPV/r, lopinavir/ritonavir.

Incubation period: from contact to symptom onset (days).

Patients G, I, and K: RT-PCR was performed to determine whether to terminate quarantine at 14 days after contact with a SARS-CoV-2 infected patient.

Clinical characteristics of presymptomatic patients with mild symptoms and asymptomatic carriers COVID-19, coronavirus disease; DM, diabetes mellitus; F, female; HTN, hypertension; M, male; N/A, not applicable; LPV/r, lopinavir/ritonavir. Incubation period: from contact to symptom onset (days). Patients G, I, and K: RT-PCR was performed to determine whether to terminate quarantine at 14 days after contact with a SARS-CoV-2 infected patient. Three patients who were asymptomatic on admission developed myalgia, fever, and a cough 1 or 2 days afterwards, without pneumonia. In two of the three patients, the viral load during the incubation period was very high (Ct value < 20), but all patients first reached Ct > 35 by day 14 (Figure 1A). In the asymptomatic SARS-CoV-2 carriers, the viral load on admission was not relatively high (Figure 1B). The median time to first RT-PCR Ct > 35 result after diagnosis in the asymptomatic carriers was 4.5 days (range 2.0–8.5 days) and all asymptomatic cases first reached a Ct > 35 within 14 days after diagnosis (Figure 1B).
Figure 1

Viral load detected in nasal–throat swabs obtained from patients infected with SARS-CoV-2. The cycle threshold (Ct) values of the RNA-dependent RNA polymerase (RdRp) gene on reverse-transcriptase polymerase chain reaction (RT-PCR) assays of nasal–throat swabs obtained from (A) three incubation period patients with mild cases of COVID-19, and (B) 10 asymptomatic carriers. Ct = 35 is the cut-off for a positive result and Ct = 40 is a negative sample; Ct = 40 was the limit of detection.

Viral load detected in nasal–throat swabs obtained from patients infected with SARS-CoV-2. The cycle threshold (Ct) values of the RNA-dependent RNA polymerase (RdRp) gene on reverse-transcriptase polymerase chain reaction (RT-PCR) assays of nasal–throat swabs obtained from (A) three incubation period patients with mild cases of COVID-19, and (B) 10 asymptomatic carriers. Ct = 35 is the cut-off for a positive result and Ct = 40 is a negative sample; Ct = 40 was the limit of detection. It was found that RT-PCR was indeterminate or negative 14 days after diagnosis in entirely asymptomatic individuals who were not given any antiviral agents. Although the presence of viral RNA in specimens does not distinguish between infective and non-infective viruses, a study found that live virus could not be detected by culture in cases with Ct > 35 (Wolfel et al., 2020). Of 309 patients in a community treatment center cohort with mild symptoms in Korea, 101 (32.7%) had negative results at 4 days after admission, and 85 (27.5%) had negative results on secondary viral testing 8 days after admission (Park et al., 2020). On the other hand, in the study by Mao et al., PCR was positive on day 19 of isolation in patients receiving antiviral agents, which might have prolonged virus detection in the two asymptomatic carriers. A modelling study estimated that 18% would be true asymptomatic cases, including the incubation period (Mizumoto et al., 2020). If the percentage of asymptomatic carriers is large, the cost of isolation for public health management may be enormous. Our data suggest that 14 days of quarantine at home after diagnosis may be adequate in entirely asymptomatic carriers. It was found that incubation period patients had high viral loads before the onset of symptoms, and that some asymptomatic carriers had an initial viral load that might be a living virus. Interestingly, this differs from the transmission of the virus causing SARS (SARS-CoV), which occurred mainly after days of illness (Lipsitch et al., 2003). On April 2, 2020, the Korea Center for Disease Control and Prevention (KCDC) guidelines for the public health management of COVID-19 patients updated its contact investigation from 1 day before symptom onset to 2 days before onset (KCDC, 2020). In the present study, it was found that there was a high viral load on RT-PCR at 2 days before symptom onset, which suggests a high risk of transmission. In summary, patients who have COVID-19 may already be infectious when there are no symptoms, and 14 days of isolation may be sufficient in entirely asymptomatic cases. We expect that these results will assist infection control practices during this pandemic.

Declarations

Funding/support: This work was supported by the Chonnam National University Hospital Biomedical Research Institute (Grant BCRI19032). Ethical statement: The analysis of cases was approved by the Institutional Review Board (IRB) of Chonnam National University Hospital (IRB No. CNUH-2020-039). Conflict of interest: The authors declare that there is no conflict of interest.
  7 in total

1.  Transmission dynamics and control of severe acute respiratory syndrome.

Authors:  Marc Lipsitch; Ted Cohen; Ben Cooper; James M Robins; Stefan Ma; Lyn James; Gowri Gopalakrishna; Suok Kai Chew; Chorh Chuan Tan; Matthew H Samore; David Fisman; Megan Murray
Journal:  Science       Date:  2003-05-23       Impact factor: 47.728

2.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

3.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

4.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

5.  Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient?

Authors:  Ren Wan; Zhi-Qun Mao; Li-Yi He; Yue-Chun Hu
Journal:  Int J Infect Dis       Date:  2020-04-03       Impact factor: 3.623

6.  Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center.

Authors:  Peong Gang Park; Chang Hyup Kim; Yoon Heo; Tae Suk Kim; Chan Woo Park; Choong Hyo Kim
Journal:  J Korean Med Sci       Date:  2020-04-06       Impact factor: 2.153

7.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.

Authors:  Kenji Mizumoto; Katsushi Kagaya; Alexander Zarebski; Gerardo Chowell
Journal:  Euro Surveill       Date:  2020-03
  7 in total
  38 in total

1.  Controlling SARS-CoV-2 in schools using repetitive testing strategies.

Authors:  Niel Hens; Pieter J K Libin; Andrea Torneri; Lander Willem; Vittoria Colizza; Cécile Kremer; Christelle Meuris; Gilles Darcis
Journal:  Elife       Date:  2022-07-05       Impact factor: 8.713

2.  SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.

Authors:  Pierre Cappy; Saadia Legrain-Jbilou; Lila Chabli; Melissa N'Debi; Pierre Gallian; Nadège Brisbarre; Josiane Pillonel; Pascal Morel; Syria Laperche
Journal:  Blood Transfus       Date:  2022-01-21       Impact factor: 5.752

3.  A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic.

Authors:  Audrey Pettifor; Bethany L DiPrete; Bonnie E Shook-Sa; Lakshmanane Premkumar; Kriste Kuczynski; Dirk Dittmer; Allison Aiello; Shannon Wallet; Robert Maile; Joyce Tan; Ramesh Jadi; Linda Pluta; Aravinda M de Silva; David J Weber; Min Kim; Arlene C Seña; Corbin D Jones
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.752

4.  Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review.

Authors:  Christina Savvides; Robert Siegel
Journal:  medRxiv       Date:  2020-06-17

Review 5.  Maternal clinical characteristics and perinatal outcomes among pregnant women with coronavirus disease 2019. A systematic review.

Authors:  Rommy H Novoa; Willy Quintana; Pedro Llancarí; Katherine Urbina-Quispe; Enrique Guevara-Ríos; Walter Ventura
Journal:  Travel Med Infect Dis       Date:  2020-11-19       Impact factor: 6.211

6.  SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19.

Authors:  Grace Lai-Hung Wong; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Yee-Kit Tse; David Shu-Cheong Hui; Shui-Shan Lee; Eng-Kiong Yeoh; Henry Lik-Yuen Chan; Grace Chung-Yan Lui
Journal:  Open Forum Infect Dis       Date:  2021-04-23       Impact factor: 3.835

Review 7.  Latest Effective Measures to Combat COVID-19: A Review.

Authors:  Fei Chen; Yingjie Liu; Bailiu Ya; Jiarui He; Taiyang Leng; Yike Sun; Qing Xin
Journal:  Iran J Public Health       Date:  2021-04       Impact factor: 1.429

Review 8.  Viral Load Difference between Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-Analysis.

Authors:  Marco Zuin; Valentina Gentili; Carlo Cervellati; Roberta Rizzo; Giovanni Zuliani
Journal:  Infect Dis Rep       Date:  2021-07-16

9.  Neonatal Infection Due to SARS-CoV-2: An Epidemiological Study in Spain.

Authors:  Belén Fernández Colomer; Manuel Sánchez-Luna; Concepción de Alba Romero; Ana Alarcón; Ana Baña Souto; Fátima Camba Longueira; María Cernada; Zenaida Galve Pradell; María González López; M Cruz López Herrera; Carmen Ribes Bautista; Laura Sánchez García; Elena Zamora Flores; Adelina Pellicer; Clara Alonso Díaz; Cristina Herraiz Perea; Dolores Sabina Romero Ramírez; Isabel de Las Cuevas Terán; Isabel Pescador Chamorro; José Luis Fernández Trisac; Luis Arruza Gómez; Luis Miguel Cardo Fernández; Mª Jesús García García; Marta Nicolás López; Miryam Hortelano López; Mónica Riaza Gómez; Natalio Hernández González; Raquel González Sánchez; Sílvia Zambudio Sert; Susana Larrosa Capacés; Vanesa Matías Del Pozo
Journal:  Front Pediatr       Date:  2020-10-23       Impact factor: 3.418

10.  Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis.

Authors:  Jingjing He; Yifei Guo; Richeng Mao; Jiming Zhang
Journal:  J Med Virol       Date:  2020-08-13       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.